Editorial – Metronomic chemotherapy

Since cytotoxic drugs are neither specific nor targeted to the cancer cells, significant research has focused on improved delivery of these drugs to tumor tissues with limited success. A search for the keyword “metronomic” identified about 172 clinical trials in various cancers, where a combination...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2017-08, Vol.400, p.203-203
Main Authors: Kumar, M.N.V. Ravi, PhD, Sood, Anil K., MD
Format: Article
Language:English
Subjects:
Administration, Metronomic
Animals
Antineoplastic Agents - administration & dosage
Bevacizumab
Cancer
Chemotherapy
Clinical trials
Cyclophosphamide
Cytotoxicity
Drug delivery
Drug dosages
Folkman, Judah
Hematology, Oncology and Palliative Medicine
Humans
Methotrexate
Monoclonal antibodies
Neoplasms - drug therapy
Neoplasms - genetics
Neoplasms - metabolism
Neoplasms - pathology
Paclitaxel
Targeted cancer therapy
Tissues
Trastuzumab
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c390t-acd59299f29a9cc42135b4bc1e49456fef082b7a1b26a3a92553dd1d86ce1ab53
cites
container_end_page 203
container_issue
container_start_page 203
container_title Cancer letters
container_volume 400
creator Kumar, M.N.V. Ravi, PhD
Sood, Anil K., MD
description Since cytotoxic drugs are neither specific nor targeted to the cancer cells, significant research has focused on improved delivery of these drugs to tumor tissues with limited success. A search for the keyword “metronomic” identified about 172 clinical trials in various cancers, where a combination of small molecule drugs administered in metronomic regimen (e.g., cyclophosphamide; methotrexate; paclitaxel) or small molecule drugs administered in metronomic regimen combined with standard biologic therapies (e.g., bevacizumab; pertuzumab; trastuzumab) (clinical...
doi_str_mv 10.1016/j.canlet.2017.03.003
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1879191850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S030438351730157X</els_id><sourcerecordid>1879191850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-acd59299f29a9cc42135b4bc1e49456fef082b7a1b26a3a92553dd1d86ce1ab53</originalsourceid><addsrcrecordid>eNpdkctKw0AUhgdRbK2-gUhBBDeJZ2YyTWYjSKkXqLhQwd0wmZzQxFzqTCp05zv4hj6JE1oVXJ3Nd37O-X5CjimEFOjkogyNbirsQgY0DoGHAHyHDGkSsyCWCeySIXCIAp5wMSAHzpUAIKJY7JMBSzgVMbAhOZtlRdfaQlfjr4_P8T12tm3aujBjs8C67RZo9XJ9SPZyXTk82s4Reb6ePU1vg_nDzd30ah4YLqELtMmEZFLmTGppTMQoF2mUGoqRjMQkxxwSlsaapmyiuZZMCJ5lNEsmBqlOBR-R803u0rZvK3SdqgtnsKp0g-3KKf-cpJImAjx6-g8t25Vt_HWKSmCRlFxyT0UbytjWOYu5Wtqi1natKKheoyrVRqPqNSrgymv0ayfb8FVaY_a79OPNA5cbAL2N9wKtMlXRFEZXr7hG93eKckyBeuyb6IugMQef8MK_ATpkg8I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1902499393</pqid></control><display><type>article</type><title>Editorial – Metronomic chemotherapy</title><source>ScienceDirect Freedom Collection</source><creator>Kumar, M.N.V. Ravi, PhD ; Sood, Anil K., MD</creator><creatorcontrib>Kumar, M.N.V. Ravi, PhD ; Sood, Anil K., MD</creatorcontrib><description>Since cytotoxic drugs are neither specific nor targeted to the cancer cells, significant research has focused on improved delivery of these drugs to tumor tissues with limited success. A search for the keyword “metronomic” identified about 172 clinical trials in various cancers, where a combination of small molecule drugs administered in metronomic regimen (e.g., cyclophosphamide; methotrexate; paclitaxel) or small molecule drugs administered in metronomic regimen combined with standard biologic therapies (e.g., bevacizumab; pertuzumab; trastuzumab) (clinical...</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2017.03.003</identifier><identifier>PMID: 28315702</identifier><language>eng</language><publisher>Ireland: Elsevier Limited</publisher><subject>Administration, Metronomic ; Animals ; Antineoplastic Agents - administration &amp; dosage ; Bevacizumab ; Cancer ; Chemotherapy ; Clinical trials ; Cyclophosphamide ; Cytotoxicity ; Drug delivery ; Drug dosages ; Folkman, Judah ; Hematology, Oncology and Palliative Medicine ; Humans ; Methotrexate ; Monoclonal antibodies ; Neoplasms - drug therapy ; Neoplasms - genetics ; Neoplasms - metabolism ; Neoplasms - pathology ; Paclitaxel ; Targeted cancer therapy ; Tissues ; Trastuzumab ; Treatment Outcome</subject><ispartof>Cancer letters, 2017-08, Vol.400, p.203-203</ispartof><rights>Elsevier B.V.</rights><rights>Copyright Elsevier Limited Aug 1, 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-acd59299f29a9cc42135b4bc1e49456fef082b7a1b26a3a92553dd1d86ce1ab53</citedby><orcidid>0000-0001-5606-401X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28315702$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumar, M.N.V. Ravi, PhD</creatorcontrib><creatorcontrib>Sood, Anil K., MD</creatorcontrib><title>Editorial – Metronomic chemotherapy</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Since cytotoxic drugs are neither specific nor targeted to the cancer cells, significant research has focused on improved delivery of these drugs to tumor tissues with limited success. A search for the keyword “metronomic” identified about 172 clinical trials in various cancers, where a combination of small molecule drugs administered in metronomic regimen (e.g., cyclophosphamide; methotrexate; paclitaxel) or small molecule drugs administered in metronomic regimen combined with standard biologic therapies (e.g., bevacizumab; pertuzumab; trastuzumab) (clinical...</description><subject>Administration, Metronomic</subject><subject>Animals</subject><subject>Antineoplastic Agents - administration &amp; dosage</subject><subject>Bevacizumab</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Cyclophosphamide</subject><subject>Cytotoxicity</subject><subject>Drug delivery</subject><subject>Drug dosages</subject><subject>Folkman, Judah</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Methotrexate</subject><subject>Monoclonal antibodies</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - genetics</subject><subject>Neoplasms - metabolism</subject><subject>Neoplasms - pathology</subject><subject>Paclitaxel</subject><subject>Targeted cancer therapy</subject><subject>Tissues</subject><subject>Trastuzumab</subject><subject>Treatment Outcome</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpdkctKw0AUhgdRbK2-gUhBBDeJZ2YyTWYjSKkXqLhQwd0wmZzQxFzqTCp05zv4hj6JE1oVXJ3Nd37O-X5CjimEFOjkogyNbirsQgY0DoGHAHyHDGkSsyCWCeySIXCIAp5wMSAHzpUAIKJY7JMBSzgVMbAhOZtlRdfaQlfjr4_P8T12tm3aujBjs8C67RZo9XJ9SPZyXTk82s4Reb6ePU1vg_nDzd30ah4YLqELtMmEZFLmTGppTMQoF2mUGoqRjMQkxxwSlsaapmyiuZZMCJ5lNEsmBqlOBR-R803u0rZvK3SdqgtnsKp0g-3KKf-cpJImAjx6-g8t25Vt_HWKSmCRlFxyT0UbytjWOYu5Wtqi1natKKheoyrVRqPqNSrgymv0ayfb8FVaY_a79OPNA5cbAL2N9wKtMlXRFEZXr7hG93eKckyBeuyb6IugMQef8MK_ATpkg8I</recordid><startdate>20170801</startdate><enddate>20170801</enddate><creator>Kumar, M.N.V. Ravi, PhD</creator><creator>Sood, Anil K., MD</creator><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5606-401X</orcidid></search><sort><creationdate>20170801</creationdate><title>Editorial – Metronomic chemotherapy</title><author>Kumar, M.N.V. Ravi, PhD ; Sood, Anil K., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-acd59299f29a9cc42135b4bc1e49456fef082b7a1b26a3a92553dd1d86ce1ab53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Metronomic</topic><topic>Animals</topic><topic>Antineoplastic Agents - administration &amp; dosage</topic><topic>Bevacizumab</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Cyclophosphamide</topic><topic>Cytotoxicity</topic><topic>Drug delivery</topic><topic>Drug dosages</topic><topic>Folkman, Judah</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Methotrexate</topic><topic>Monoclonal antibodies</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - genetics</topic><topic>Neoplasms - metabolism</topic><topic>Neoplasms - pathology</topic><topic>Paclitaxel</topic><topic>Targeted cancer therapy</topic><topic>Tissues</topic><topic>Trastuzumab</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumar, M.N.V. Ravi, PhD</creatorcontrib><creatorcontrib>Sood, Anil K., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumar, M.N.V. Ravi, PhD</au><au>Sood, Anil K., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Editorial – Metronomic chemotherapy</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2017-08-01</date><risdate>2017</risdate><volume>400</volume><spage>203</spage><epage>203</epage><pages>203-203</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Since cytotoxic drugs are neither specific nor targeted to the cancer cells, significant research has focused on improved delivery of these drugs to tumor tissues with limited success. A search for the keyword “metronomic” identified about 172 clinical trials in various cancers, where a combination of small molecule drugs administered in metronomic regimen (e.g., cyclophosphamide; methotrexate; paclitaxel) or small molecule drugs administered in metronomic regimen combined with standard biologic therapies (e.g., bevacizumab; pertuzumab; trastuzumab) (clinical...</abstract><cop>Ireland</cop><pub>Elsevier Limited</pub><pmid>28315702</pmid><doi>10.1016/j.canlet.2017.03.003</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-5606-401X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0304-3835
ispartof Cancer letters, 2017-08, Vol.400, p.203-203
issn 0304-3835
1872-7980
language eng
recordid cdi_proquest_miscellaneous_1879191850
source ScienceDirect Freedom Collection
subjects Administration, Metronomic
Animals
Antineoplastic Agents - administration & dosage
Bevacizumab
Cancer
Chemotherapy
Clinical trials
Cyclophosphamide
Cytotoxicity
Drug delivery
Drug dosages
Folkman, Judah
Hematology, Oncology and Palliative Medicine
Humans
Methotrexate
Monoclonal antibodies
Neoplasms - drug therapy
Neoplasms - genetics
Neoplasms - metabolism
Neoplasms - pathology
Paclitaxel
Targeted cancer therapy
Tissues
Trastuzumab
Treatment Outcome
title Editorial – Metronomic chemotherapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T10%3A27%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Editorial%20%E2%80%93%20Metronomic%20chemotherapy&rft.jtitle=Cancer%20letters&rft.au=Kumar,%20M.N.V.%20Ravi,%20PhD&rft.date=2017-08-01&rft.volume=400&rft.spage=203&rft.epage=203&rft.pages=203-203&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2017.03.003&rft_dat=%3Cproquest_cross%3E1879191850%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c390t-acd59299f29a9cc42135b4bc1e49456fef082b7a1b26a3a92553dd1d86ce1ab53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1902499393&rft_id=info:pmid/28315702&rfr_iscdi=true